Lanthio Pharma is a Dutch biopharmaceutical company committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity.
Utilizing our technology we are building a growing pipeline of stabilized, receptor-specific lanthipeptides.
Lanthio’s lead product, MOR107 (formerly LP2), is a selective AT2 receptor agonist, in clinical development.
Lanthio Pharma is located in the city of Groningen in the north of the Netherlands very close to Groningen-Airport which has direct flight connections with Munich, London-Southend and Copenhagen.
On May 7th, 2015 MorphoSys AG announced that it has acquired all outstanding shares of Lanthio Pharma BV
Read full story